Shiangjiin Leaw

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Yunpeng Yang, Jianji Pan, Hui Wang et al. · Cancer Cell · 2023 · 191 citations · Full text

R/m Npc, Immunology, Pathology +16

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng, Yun Fan, Yanqiu Zhao et al. · Journal of Thoracic Oncology · 2024 · 104 citations · Full text

Phase 3, Clinical Therapeutic, Pharmacology +7

XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population

Zhonghua Wang, Binghe Xu, Dongxin Lin et al. · Lung Cancer · 2008 · 63 citations

Oncology, Xrcc1 Polymorphisms, Pathology +9

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

Zhonghua Wang, Jingsong Lu, Shiangjiin Leaw et al. · Cancer Chemotherapy and Pharmacology · 2011 · 51 citations

Breast Oncology, All-oral Combination, Medicine +11

Internal mammary lymph node recurrence: rare but characteristic metastasis site in breast cancer

Lei Chen, Yajia Gu, Shiangjiin Leaw et al. · BMC Cancer · 2010 · 37 citations · Full text